Clinical Trial Update: Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating eltrombopag as a treatment for low-risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia with TET2 mutations; cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: Abhay Singh, MD MPH | Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Status: RECRUITING